Centre D'Etude De La Peau Et Du Cheveu
- Address
- lock Available on a paid plan
Skin and Connective Tissue Diseases
At the Centre D'Etude De La Peau Et Du Cheveu in Paris, clinical research focuses on dermatology with an emphasis on atopic dermatitis. These studies are exploring whether new targeted treatments can improve symptom control and provide longer-term benefit for people living with moderate-to-severe disease.
- Evaluating the effectiveness of a new therapy for atopic dermatitis
- Assessing long-term safety and ongoing disease control in skin disease research
- Studying treatment options for patients who have not responded well to previous therapies
The site’s work in cutaneous disorders is centered on improving care for patients with persistent inflammatory skin conditions.
Immune System Diseases
Research at this hospital-based dermatology site also includes immune-mediated disease studies, reflecting the role of the immune system in chronic inflammatory skin conditions. The main goal is to better understand and treat diseases driven by immune dysfunction.
- Testing targeted immune-modulating treatments for difficult-to-control inflammatory disease
- Comparing active therapy with placebo to measure clinical benefit
- Supporting treatment selection for patients with complex immune-related skin problems
These efforts help advance more precise care for patients with immune system diseases seen in everyday dermatology practice.
Analytical, Diagnostic and Therapeutic Techniques and Equipment
The Centre D'Etude De La Peau Et Du Cheveu is also involved in research that uses clinical assessment tools to guide treatment decisions in folliculitis decalvans and other hard-to-treat scalp disorders. This work aims to improve how response to therapy is measured and how effective treatments are selected.
- Using structured clinical scoring to track improvement in folliculitis decalvans
- Evaluating targeted therapies for patients with limited treatment options
- Refining diagnostic and monitoring approaches in dermatology
Overall, the research combines diagnostic evaluation and treatment assessment to support better outcomes in challenging hair and scalp disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre D'Etude De La Peau Et Du Cheveu
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Subcutaneous Amlitelimab in Moderate-to-Severe Atopic Dermatitis with Background Topical Corticosteroids in Adolescents and Adults | Sanofi-Aventis Recherche & Developpement | Phase III | Recruiting | Jun 2024 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Amlitelimab | 3 | Unknown | 2022-11-10 | 2024-06-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.